glp 1 for iih GLP-1 medications and pseudotumor cerebri / idiopathic intracranial hypertension #pseudotumorcerebri #iih Treatment with GLP-1 receptor agonists

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

- Mechanism of Action & Protocol.

This shift is not just about the numbersits changing how physicians and patients think about managing T2D and its many related comorbidities

A-RDN induced significant increases in diuretic and natriuretic responses to GLP-1 in HF (urine flow 96.01.9 vs

$LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes More Info:

This was an exploratory study of the IIH:Pressure trial (ISTCRN 12678718)